Shoulder Innovations, Inc. (SI) · Nov 5, 2026 · Earnings
Beat — Revenue $16.2M vs ~$15.44M consensus; EPS $(0.34) vs $(0.49) consensus
Shoulder Innovations earnings beat published Q3 estimates, with 38% revenue growth and another full-year guidance raise despite ongoing operating losses.
Shoulder Innovations is a commercial-stage shoulder-arthroplasty specialist trying to expand surgeon adoption while building a broader ecosystem around implants, enabling tools and eventually its InSet Neo robotic platform. Its last reported quarter had already lifted 2026 revenue guidance to $67 million-$69 million, so this filing is testing whether that commercial ramp is accelerating rather than merely continuing.
The quarter cleared the published bar on both revenue and adjusted earnings. Revenue rose 38% to $16.2 million, ahead of the approximately $15.44 million published estimate, while reported EPS of $(0.34) was better than the approximately $(0.49) estimate. The revenue growth came from more implant systems sold, new surgeon customers, higher utilization among existing customers and higher average selling prices.
| Q3 2026 | Q3 2025 | Consensus / Prior guide | |
|---|---|---|---|
| Net revenue (Financial Highlights) | $16.191M (+37.7%) | $11.756M | ~$15.44M |
| Net loss per share (Financial Highlights) | $(0.34) | $(0.64) | $(0.49) |
| Gross margin (Results discussion) | 78.5% (+2.3 pts) | 76.2% | |
| Operating loss (Financial Highlights) | $(7.597M) | $(7.641M) | |
| Adjusted EBITDA (Non-GAAP reconciliation) | $(5.487M) | $(7.510M) | |
| FY26 net revenue guidance (Outlook) | $68M-$70M | $67M-$69M |
The guidance raise is the most important business signal. Management lifted the full-year revenue range by $1 million at both ends, implying the commercial ramp is tracking ahead of the already-raised outlook. The filing also says new surgeons were added ahead of plan and utilization increased within the existing customer base, which is a better quality of growth signal than relying only on pricing.
Profitability is improving, but the company is still funding expansion rather than harvesting it. Gross margin increased to 78.5%, and the adjusted EBITDA loss narrowed to $5.5 million from $7.5 million. However, the GAAP operating loss was essentially unchanged at $7.6 million because SG&A rose 14% and R&D more than doubled to support commercial expansion and InSet Neo development.
The product pipeline adds strategic upside, but it is not yet commercial revenue. InSet Go has completed its first successful cases, while InSet Neo remains a planned 2027 FDA submission rather than an approved or launched product. That makes the pipeline supportive of the current story, not a reason to rewrite it today. 〔0〕
Bottom line: This was a genuine execution beat: demand is running ahead of expectations and management raised the outlook again. The main limitation is that stronger sales have not yet translated into a smaller GAAP operating loss because SI is still investing heavily in its commercial and product platform.
FDA submission for InSet Neo, planned for 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!